Developer of cytokine fusion proteins for chronic pain treatment.
| Date | Round | Amount |
|---|---|---|
| Dec 2021 | Series A Dutch biotech Synerkine Pharma raised a EUR 3.5M Series A extension led by Flerie Invest, with Thuja Capital and Utrecht Holdings, to advance its lead compound SK-01. | $4.1M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.